Clínica Universidad de Navarra at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Clínica Universidad de Navarra takes part in 8 sessions at ESMO 2026 in Madrid. Its program centres on RAS-targeted therapies in lung and pancreatic cancer and on treatment decisions in EGFR-mutated non-small cell lung cancer. Other sessions cover shared decision-making and patient communication in adjuvant therapy, radioligand updates and the administrative burden of running clinical trials.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Private university hospital of the University of Navarra in Pamplona, Spain, with a cancer centre and a second site in Madrid.
Talk
Sat Oct 24
09:10–09:30
Overcoming administrative burden of clinical trials
Solutions to overcome barriers of access to clinical trials
Satellite
Sat Oct 24
14:05–14:25
Oncologist’s update: translating frontline EGFR trial evidence into treatment decisions
J&J - Collaborative Precision Care in EGFR-mutated NSCLC. A Multidisciplinary Approach
Lung & thoracic cancersNursing & supportive care
Chair
Sat Oct 24
14:45–16:15
Proffered paper: Gynaecological cancers
with Memorial Sloan Kettering Cancer Center
Gynaecological cancers
Chair
Sun Oct 25
08:30–10:00
Rapid oral 1: Basic science and translational research
with Barts Cancer Institute, Queen Mary University of London, University of Luxembourg
Biomarkers & precision oncology
Abstract
Sun Oct 25
09:19–09:31
Invited Discussant 4247RO
Rapid oral 1: Basic science and translational research
Biomarkers & precision oncology
Satellite
Sun Oct 25
13:20–13:40
Shared Decision-Making in Adjuvant Therapy: Balancing Recurrence Risk and Treatment
Lilly - Translating treatment decisions into patient Palacio Municipal outcomes: practical approaches to communication, adherence and care delivery
Nursing & supportive care
Satellite
Sun Oct 25
14:00–14:20
What Matters Most to Patients? Bridging Communication Gaps to Improve Outcomes
Lilly - Translating treatment decisions into patient Palacio Municipal outcomes: practical approaches to communication, adherence and care delivery · with START Center for Cancer Care, The Global Gene, University of South-Eastern Norway
Nursing & supportive care
Talk
Mon Oct 26
08:45–09:00
Updates on radioligands
New targets and strategies
Satellite
Mon Oct 26
18:30–18:35
Introduction
Revolution Medicines - Advances in RAS-targeted therapies: emerging clinical data and future directions in NSCLC and PDAC · with Hospital Clínic de Barcelona, Klinik Floridsdorf
Lung & thoracic cancersGastrointestinal cancers
Satellite
Mon Oct 26
18:30–20:00
Revolution Medicines - Advances in RAS-targeted therapies: emerging clinical data and future directions in NSCLC and PDAC
with Hospital Clínic de Barcelona, Klinik Floridsdorf
Lung & thoracic cancersGastrointestinal cancers
Satellite
Mon Oct 26
18:35–19:00
The role of RAS as an oncogenic driver in cancer pathogenesis and its therapeutic targeting
Revolution Medicines - Advances in RAS-targeted therapies: emerging clinical data and future directions in NSCLC and PDAC
Lung & thoracic cancersGastrointestinal cancers
Satellite
Mon Oct 26
19:45–20:00
Conclusions and Q&A
Revolution Medicines - Advances in RAS-targeted therapies: emerging clinical data and future directions in NSCLC and PDAC · with Hospital Clínic de Barcelona, Klinik Floridsdorf
Lung & thoracic cancersGastrointestinal cancers
Talk
Tue Oct 27
10:20–10:40
Gynaecological cancers
Scientific Congress Highlights 2

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Clínica Universidad de Navarra

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction